ALX Oncology
ALXO
104 hedge funds and large institutions have $1.82B invested in ALX Oncology in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 11 closing their positions.
288% more call options, than puts
Call options by funds: $3.16M | Put options by funds: $815K
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
12% more funds holding
Funds holding: 93 → 104 (+11)
0.7% less ownership
Funds ownership: 83.51% → 82.81% (-0.7%)
26% less capital invested
Capital invested by funds: $2.47B → $1.82B (-$646M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$20.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.63M |
| 5 |
Morgan Stanley
New York
|
+$5.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$58M |
| 2 |
BlackRock
New York
|
-$15.9M |
| 3 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$15.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$8.87M |
| 5 |
Goldman Sachs
New York
|
-$7M |
ALXO Hedge Fund Activity: Q2 2021 in Review
104 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q2 2021, worth a combined $1.82B — down 26% from $2.47B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ALXO positions and 11 closed out — a net gain of 11 holders — while 38 added to existing stakes and 26 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $20.9M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $58M sold.
- 104 institutional investors held ALX Oncology (ALXO) as of Q2 2021, up from 93 in Q1 2021.
- Funds reported $1.82B of ALX Oncology stock for Q2 2021, down 26% quarter-over-quarter.
- 22 funds opened new ALX Oncology positions in Q2 2021 and 11 closed out, a net change of +11 holders.
- The largest ALX Oncology buyer in Q2 2021 was Eventide Asset Management, an estimated $20.9M added.
- The largest ALX Oncology seller in Q2 2021 was Foresite Capital Management IV, an estimated $58M sold.
Based on aggregated 13F filings for Q2 2021.